<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Innovent Biologics, Inc. — News on 6ix</title>
<link>https://6ix.com/company/innovent-biologics-inc</link>
<description>Latest news and press releases for Innovent Biologics, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 00:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/innovent-biologics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836871778dffbe2df16abd3.webp</url>
<title>Innovent Biologics, Inc.</title>
<link>https://6ix.com/company/innovent-biologics-inc</link>
</image>
<item>
<title>Innovent to Present New Clinical Data of IBI363（PD-1/IL-2α-biased bispecific fusion protein） at the 2026 ASCO Annual Meeting</title>
<link>https://6ix.com/company/innovent-biologics-inc/news/innovent-to-present-new-clinical-data-of-ibi363pd-1il-2a-biased-bispecific-fusion-protein-at-the-2026-asco-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/innovent-biologics-inc/news/innovent-to-present-new-clinical-data-of-ibi363pd-1il-2a-biased-bispecific-fusion-protein-at-the-2026-asco-annual-meeting</guid>
<pubDate>Wed, 22 Apr 2026 00:00:00 GMT</pubDate>
<description>Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that clinical data for its first-in-class IBI363 (PD-1/IL-2α-biased bispecific fusion protein) * as well as TYVYT® (sintilimab injection)** will be presented at the 2026 American Society of Clinical Oncology (ASCO)</description>
</item>
<item>
<title>Immune Resetting: B-Cell Mediated & Beyond Summit 2026 Oral Presentation: Innovent Biologics Announces Pre-Clinical Results of IBI3055, a Tri-specific T Cell Engager Targeting Autoimmune Diseases</title>
<link>https://6ix.com/company/innovent-biologics-inc/news/immune-resetting-b-cell-mediated-and-beyond-summit-2026-oral-presentation-innovent-biologics-announces-pre-clinical-results-of-ibi3055-a-tri-specific-t-cell-engager-targeting-autoimmune-diseases</link>
<guid isPermaLink="true">https://6ix.com/company/innovent-biologics-inc/news/immune-resetting-b-cell-mediated-and-beyond-summit-2026-oral-presentation-innovent-biologics-announces-pre-clinical-results-of-ibi3055-a-tri-specific-t-cell-engager-targeting-autoimmune-diseases</guid>
<pubDate>Fri, 10 Apr 2026 00:00:00 GMT</pubDate>
<description>Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, presented for the first time the preclinical data of IBI3055, a proprietary anti-CD19/BCMA/CD3 tri-specific T cell engager for the treatment of autoimmune diseases, as an oral presentation at the 2026 Immune Resetting:</description>
</item>
<item>
<title>Innovent's Partner Ollin Biosciences Announces Final Data from Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema</title>
<link>https://6ix.com/company/innovent-biologics-inc/news/innovents-partner-ollin-biosciences-announces-final-data-from-randomized-head-to-head-study-of-ibi324-compared-to-faricimab-vabysmo-in-wet-age-related-macular-degeneration-and-diabetic-macular-edema</link>
<guid isPermaLink="true">https://6ix.com/company/innovent-biologics-inc/news/innovents-partner-ollin-biosciences-announces-final-data-from-randomized-head-to-head-study-of-ibi324-compared-to-faricimab-vabysmo-in-wet-age-related-macular-degeneration-and-diabetic-macular-edema</guid>
<pubDate>Tue, 31 Mar 2026 00:00:00 GMT</pubDate>
<description>Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, today announced that the company's partner Ollin reported final, 20-week study completion data from its randomized, head-to-head Phase 1b JADE clinical study comparing OLN324(Innovent R&D code IBI324) , a higher-potenc</description>
</item>
<item>
<title>Innovent Announces 2025 Annual Results and Business Updates</title>
<link>https://6ix.com/company/innovent-biologics-inc/news/innovent-announces-2025-annual-results-and-business-updates</link>
<guid isPermaLink="true">https://6ix.com/company/innovent-biologics-inc/news/innovent-announces-2025-annual-results-and-business-updates</guid>
<pubDate>Thu, 26 Mar 2026 10:00:00 GMT</pubDate>
<description>Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announces its 2025 annual results and long-term strategic blueprint.</description>
</item>
<item>
<title>The Phase 3 Registration STAR Study of Efdamrofusp Alfa (IBI302) Met its Primary Endpoint, Making it the First Self-developed Extended-interval Treatment for nAMD in China</title>
<link>https://6ix.com/company/innovent-biologics-inc/news/the-phase-3-registration-star-study-of-efdamrofusp-alfa-ibi302-met-its-primary-endpoint-making-it-the-first-self-developed-extended-interval-treatment-for-namd-in-china</link>
<guid isPermaLink="true">https://6ix.com/company/innovent-biologics-inc/news/the-phase-3-registration-star-study-of-efdamrofusp-alfa-ibi302-met-its-primary-endpoint-making-it-the-first-self-developed-extended-interval-treatment-for-namd-in-china</guid>
<pubDate>Tue, 24 Mar 2026 00:00:00 GMT</pubDate>
<description>Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announces that the Phase 3 clinical study (STAR) of efdamrofusp alfa injection (recombinant human vascular endothelial growth factor receptor [VEGFR]/human complement receptor 1 [CR1] fusion protein, R&D code: IBI302) in the Chinese patients with neovascular a</description>
</item>
<item>
<title>Innovent Announces First Participant Dosed of IBI128 (Tigulixostat, XOI) in Phase 3 Clinical Study</title>
<link>https://6ix.com/company/innovent-biologics-inc/news/innovent-announces-first-participant-dosed-of-ibi128-tigulixostat-xoi-in-phase-3-clinical-study</link>
<guid isPermaLink="true">https://6ix.com/company/innovent-biologics-inc/news/innovent-announces-first-participant-dosed-of-ibi128-tigulixostat-xoi-in-phase-3-clinical-study</guid>
<pubDate>Mon, 23 Mar 2026 00:00:00 GMT</pubDate>
<description>Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the xanthine oxidase inhibitor (XOI) Tigulixostat(R&D code: IBI128) have the first participant dosed in a Phase 3 clinical study in head-to-head comparison of febuxostat, aiming to provide a better treatment op</description>
</item>
<item>
<title>Jaypirca® (Pirtobrutinib) Approved in China for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma</title>
<link>https://6ix.com/company/innovent-biologics-inc/news/jaypircar-pirtobrutinib-approved-in-china-for-the-treatment-of-relapsed-or-refractory-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma</link>
<guid isPermaLink="true">https://6ix.com/company/innovent-biologics-inc/news/jaypircar-pirtobrutinib-approved-in-china-for-the-treatment-of-relapsed-or-refractory-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma</guid>
<pubDate>Mon, 02 Mar 2026 00:00:00 GMT</pubDate>
<description>Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announces the non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, Jaypirca® (pirtobrutinib), has received approval by the National Medical Products Administration (NMPA) in China for a new indication for</description>
</item>
<item>
<title>Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for First Line Treatment of HER2-positive Breast Cancer</title>
<link>https://6ix.com/company/innovent-biologics-inc/news/innovent-dosed-first-participant-in-phase-3-clinical-study-of-ibi354-novel-her2-adc-for-first-line-treatment-of-her2-positive-breast-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/innovent-biologics-inc/news/innovent-dosed-first-participant-in-phase-3-clinical-study-of-ibi354-novel-her2-adc-for-first-line-treatment-of-her2-positive-breast-cancer</guid>
<pubDate>Fri, 13 Feb 2026 00:00:00 GMT</pubDate>
<description>Innovent Biologics, Inc. ("Innovent",HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that the first participant has been successfully dosed in the pivotal Phase 3 clinical study (HeriCare-Breast01). The trial is evaluating the company's developed IBI354 (HER2 Monoclonal Antibody-Camptothecin Derivati</description>
</item>
<item>
<title>Innovent Announces Strategic Collaboration with Lilly to Develop New Medicines Globally in Oncology and Immunology</title>
<link>https://6ix.com/company/innovent-biologics-inc/news/innovent-announces-strategic-collaboration-lilly-100500309</link>
<guid isPermaLink="true">https://6ix.com/company/innovent-biologics-inc/news/innovent-announces-strategic-collaboration-lilly-100500309</guid>
<pubDate>Sun, 08 Feb 2026 10:05:00 GMT</pubDate>
<description>Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, today announced a strategic collaboration with Eli Lilly and Company ("Lilly") to advance novel medicines in oncology and immunology. This agreement marks the seventh collaboration between the two companies, deepening a</description>
</item>
<item>
<title>Innovent Announces IBI3003 (GPRC5D/BCMA/CD3 Trispecific Antibody) Receives Fast Track Designation from the U.S. FDA for Relapsed or Refractory Multiple Myeloma</title>
<link>https://6ix.com/company/innovent-biologics-inc/news/innovent-announces-ibi3003-gprc5dbcmacd3-trispecific-antibody-receives-fast-track-designation-from-the-us-fda-for-relapsed-or-refractory-multiple-myeloma</link>
<guid isPermaLink="true">https://6ix.com/company/innovent-biologics-inc/news/innovent-announces-ibi3003-gprc5dbcmacd3-trispecific-antibody-receives-fast-track-designation-from-the-us-fda-for-relapsed-or-refractory-multiple-myeloma</guid>
<pubDate>Tue, 27 Jan 2026 00:00:00 GMT</pubDate>
<description>Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announced that its anti-GPRC5D/BCMA/CD3 tri-specific antibody IBI3003 has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA). This designation applies to the treatment of relapsed or r</description>
</item>
<item>
<title>Innovent's Partner Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration</title>
<link>https://6ix.com/company/innovent-biologics-inc/news/innovents-partner-ollin-biosciences-announces-000000681</link>
<guid isPermaLink="true">https://6ix.com/company/innovent-biologics-inc/news/innovents-partner-ollin-biosciences-announces-000000681</guid>
<pubDate>Fri, 09 Jan 2026 00:00:00 GMT</pubDate>
<description>Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, today announced that the company's partner Ollin reported positive topline results from its randomized, head-to-head Phase 1b JADE clinical study comparing IBI324 (Ollin R&D code:OLN324), a next-generation VEGF/Ang2 bi</description>
</item>
<item>
<title>China's First Domestic Anti-CTLA-4 Monoclonal Antibody, Innovent's TABOSUN® (Ipilimumab N01 Injection) Received NMPA Approval</title>
<link>https://6ix.com/company/innovent-biologics-inc/news/chinas-first-domestic-anti-ctla-4-monoclonal-antibody-innovents-tabosunr-ipilimumab-n01-injection-received-nmpa-approval</link>
<guid isPermaLink="true">https://6ix.com/company/innovent-biologics-inc/news/chinas-first-domestic-anti-ctla-4-monoclonal-antibody-innovents-tabosunr-ipilimumab-n01-injection-received-nmpa-approval</guid>
<pubDate>Thu, 25 Dec 2025 08:44:00 GMT</pubDate>
<description>Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that the New Drug Application (NDA) for TABOSUN® (ipilimumab N01 injection; R&D Code: IBI310), the first domestic cytotoxic lymphocyte-associated antigen-4 (CTLA-4) monoclonal antibody (mAb), has been approved by C</description>
</item>
<item>
<title>Nature | Two Phase 3 Clinical Results of Mazdutide (GLP-1/GCG Dual Receptor Agonist) in Chinese Adults with Type 2 Diabetes Have Been Back-to-Back Published in Nature</title>
<link>https://6ix.com/company/innovent-biologics-inc/news/nature-or-two-phase-3-clinical-results-of-mazdutide-glp-1gcg-dual-receptor-agonist-in-chinese-adults-with-type-2-diabetes-have-been-back-to-back-published-in-nature</link>
<guid isPermaLink="true">https://6ix.com/company/innovent-biologics-inc/news/nature-or-two-phase-3-clinical-results-of-mazdutide-glp-1gcg-dual-receptor-agonist-in-chinese-adults-with-type-2-diabetes-have-been-back-to-back-published-in-nature</guid>
<pubDate>Thu, 18 Dec 2025 00:00:00 GMT</pubDate>
<description>Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces that the results of two Phase 3 clinical studies of mazdutide, the world's first approved glucagon (GCG)/glucagon-like peptide-1 (GLP-1) dual receptor agonist, in Chinese adults with type 2 diabetes (T2D) (DREAMS</description>
</item>
<item>
<title>Mazdutide Demonstrates Significant Weight Loss and Metabolic Benefits in Phase 1b Clinical Trial in Chinese Adolescents with Obesity</title>
<link>https://6ix.com/company/innovent-biologics-inc/news/mazdutide-demonstrates-significant-weight-loss-and-metabolic-benefits-in-phase-1b-clinical-trial-in-chinese-adolescents-with-obesity</link>
<guid isPermaLink="true">https://6ix.com/company/innovent-biologics-inc/news/mazdutide-demonstrates-significant-weight-loss-and-metabolic-benefits-in-phase-1b-clinical-trial-in-chinese-adolescents-with-obesity</guid>
<pubDate>Fri, 12 Dec 2025 00:00:00 GMT</pubDate>
<description>Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announced that the Phase 1b clinical study of mazdutide injection (a glucagon-like peptide-1 [GLP-1] and glucagon [GCG] dual receptor agonist, R&D code: IBI362) in Chinese adolescents with obesity met its primary endpoint.</description>
</item>
<item>
<title>Innovent Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3011, a Recombinant Anti-Human Interleukin 1 Receptor Accessory Protein Monoclonal Antibody</title>
<link>https://6ix.com/company/innovent-biologics-inc/news/innovent-announces-first-participant-dosed-in-a-phase-1-clinical-trial-of-ibi3011-a-recombinant-anti-human-interleukin-1-receptor-accessory-protein-monoclonal-antibody</link>
<guid isPermaLink="true">https://6ix.com/company/innovent-biologics-inc/news/innovent-announces-first-participant-dosed-in-a-phase-1-clinical-trial-of-ibi3011-a-recombinant-anti-human-interleukin-1-receptor-accessory-protein-monoclonal-antibody</guid>
<pubDate>Wed, 10 Dec 2025 00:26:00 GMT</pubDate>
<description>Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major disease areas, announced that the first participant has been successfully dosed in a Phase 1 clinical trial of IBI3011, an anti-human Interleukin 1 receptor accessory protein (IL-1RAP) monoclonal antibody developed by Innovent.</description>
</item>
<item>
<title>Innovent Announces PECONDLE® (Picankibart Injection) Phase 3 Study (CLEAR-2) Meets Endpoints, Delivering Superior Long-Term Management Solution for Moderate-to-Severe Psoriasis</title>
<link>https://6ix.com/company/innovent-biologics-inc/news/innovent-announces-pecondler-picankibart-injection-phase-3-study-clear-2-meets-endpoints-delivering-superior-long-term-management-solution-for-moderate-to-severe-psoriasis</link>
<guid isPermaLink="true">https://6ix.com/company/innovent-biologics-inc/news/innovent-announces-pecondler-picankibart-injection-phase-3-study-clear-2-meets-endpoints-delivering-superior-long-term-management-solution-for-moderate-to-severe-psoriasis</guid>
<pubDate>Tue, 09 Dec 2025 00:00:00 GMT</pubDate>
<description>Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces that that PECONDLE® (picankibart injection, R&D code: IBI112), its self-developed recombinant anti-interleukin-23p19 subunit monoclonal antibody, achieved both primary and key secondary efficacy endpoints in the</description>
</item>
<item>
<title>ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma</title>
<link>https://6ix.com/company/innovent-biologics-inc/news/ash-2025-oral-presentation-innovent-biologics-announces-initial-results-of-the-first-in-human-phase-1-study-of-trispecific-antibody-ibi3003-in-relapsed-or-refractory-multiple-myeloma</link>
<guid isPermaLink="true">https://6ix.com/company/innovent-biologics-inc/news/ash-2025-oral-presentation-innovent-biologics-announces-initial-results-of-the-first-in-human-phase-1-study-of-trispecific-antibody-ibi3003-in-relapsed-or-refractory-multiple-myeloma</guid>
<pubDate>Mon, 08 Dec 2025 01:02:00 GMT</pubDate>
<description>Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, announced the initial data of the first-in-human trial of IBI3003, a novel trispecific antibody targeting G protein-coupled receptor C5D (GPRC5D), B-cell maturation antigen (BCMA), and CD3 for the treatment of relapsed</description>
</item>
<item>
<title>Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List</title>
<link>https://6ix.com/company/innovent-biologics-inc/news/innovent-announces-inclusion-of-seven-innovative-drugs-including-tyvyt-new-indication-and-sycume-in-chinas-national-reimbursement-drug-list</link>
<guid isPermaLink="true">https://6ix.com/company/innovent-biologics-inc/news/innovent-announces-inclusion-of-seven-innovative-drugs-including-tyvyt-new-indication-and-sycume-in-chinas-national-reimbursement-drug-list</guid>
<pubDate>Sun, 07 Dec 2025 03:40:00 GMT</pubDate>
<description>Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that seven of its innovative products have been included in the updated 2025 National Reimbursement Drug List (NRDL). This list features a new indication of TYVYT® (sintilimab injection), and first-time inclusions</description>
</item>
<item>
<title>Innovent Biologics Announces Closing of Global Strategic Partnership with Takeda for Next-Generation IO and ADC Therapies</title>
<link>https://6ix.com/company/innovent-biologics-inc/news/innovent-biologics-announces-closing-of-global-strategic-partnership-with-takeda-for-next-generation-io-and-adc-therapies</link>
<guid isPermaLink="true">https://6ix.com/company/innovent-biologics-inc/news/innovent-biologics-announces-closing-of-global-strategic-partnership-with-takeda-for-next-generation-io-and-adc-therapies</guid>
<pubDate>Thu, 04 Dec 2025 23:38:00 GMT</pubDate>
<description>Innovent Biologics (HKEX: 01801) today announced that the global strategic collaboration with Takeda (TSE: 4502, NYSE: TAK) has closed and become effective following the satisfaction of all closing conditions. The collaboration, initially announced on October 22, 2025, aims to accelerate the global development and commercialization of Innovent's next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies, including the global partnership on IBI363 (PD-1/IL-2α-bias) and IBI34</description>
</item>
<item>
<title>China's First Domestic IL-23p19 Monoclonal Antibody: Innovent's PECONDLE® (Picankibart Injection) Received NMPA Approval</title>
<link>https://6ix.com/company/innovent-biologics-inc/news/chinas-first-domestic-il-23p19-monoclonal-antibody-innovents-pecondler-picankibart-injection-received-nmpa-approval</link>
<guid isPermaLink="true">https://6ix.com/company/innovent-biologics-inc/news/chinas-first-domestic-il-23p19-monoclonal-antibody-innovents-pecondler-picankibart-injection-received-nmpa-approval</guid>
<pubDate>Fri, 28 Nov 2025 09:06:00 GMT</pubDate>
<description>Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces that China's National Medical Products Administration (NMPA) has approved PECONDLE® (picankibart injection), a recombinant anti-interleukin-23p19 subunit (IL-23p19) antibody, for the treatment of moderate-to-seve</description>
</item>
</channel>
</rss>